Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 9 July 1993:
Vol. 261. no. 5118, pp. 212 - 215
DOI: 10.1126/science.8327892
Prev | Table of Contents | Next

Articles

Science, Vol 261, Issue 5118, 212-215
Copyright © 1993 by American Association for the Advancement of Science

articles

Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates

PA Trail, D Willner, SJ Lasch, AJ Henderson, S Hofstead, AM Casazza, RA Firestone, I Hellstrom, and KE Hellstrom

Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543.

Immunoconjugates (BR96-DOX) were prepared between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin. The monoclonal antibody binds an antigen related to Lewis Y that is abundantly expressed at the surface of cells from many human carcinomas; it has a high degree of tumor selectivity and is internalized after binding. BR96-DOX induced complete regressions and cures of xenografted human lung, breast, and colon carcinomas growing subcutaneously in athymic mice and cured 70 percent of mice bearing extensive metastases of a human lung carcinoma. Also, BR96-DOX cured 94 percent of athymic rats with subcutaneous human lung carcinoma, even though the rats, like humans and in contrast to mice, expressed the BR96 target antigen in normal tissues.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms.
R. Stein, M. J. Mattes, T. M. Cardillo, H. J. Hansen, C.-H. Chang, J. Burton, S. Govindan, and D. M. Goldenberg (2007)
Clin. Cancer Res. 13, 5556s-5563s
   Abstract »    Full Text »    PDF »
Folate Receptor-Specific Antitumor Activity of EC131, a Folate-Maytansinoid Conjugate.
J. A. Reddy, E. Westrick, H. K.R. Santhapuram, S. J. Howard, M. L. Miller, M. Vetzel, I. Vlahov, R. V.J. Chari, V. S. Goldmacher, and C. P. Leamon (2007)
Cancer Res. 67, 6376-6382
   Abstract »    Full Text »    PDF »
A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen.
A. M. Scott, N. Tebbutt, F.-T. Lee, T. Cavicchiolo, Z. Liu, S. Gill, A. M.T. Poon, W. Hopkins, F. E. Smyth, C. Murone, et al. (2007)
Clin. Cancer Res. 13, 3286-3292
   Abstract »    Full Text »    PDF »
Enhanced Efficacy of 90Y-Radiolabeled Anti-Lewis Y Humanized Monoclonal Antibody hu3S193 and Paclitaxel Combined-Modality Radioimmunotherapy in a Breast Cancer Model.
M. P. Kelly, F. T. Lee, F. E. Smyth, M. W. Brechbiel, and A. M. Scott (2006)
J. Nucl. Med. 47, 716-725
   Abstract »    Full Text »    PDF »
Doxorubicin-Conjugated Anti-Midkine Monoclonal Antibody as a Potential Anti-Tumor Drug.
K. Inoh, H. Muramatsu, S. Torii, S. Ikematsu, M. Oda, H. Kumai, S. Sakuma, T. Inui, T. Kimura, and T. Muramatsu (2006)
Jpn. J. Clin. Oncol. 36, 207-211
   Abstract »    Full Text »    PDF »
Clinical Evaluation of BR96 sFv-PE40 Immunotoxin Therapy in Canine Models of Spontaneously Occurring Invasive Carcinoma.
C. J. Henry, M. S. Buss, I. Hellstrom, K. E. Hellstrom, W. G. Brewer, J. N. Bryan, and C. B. Siegall (2005)
Clin. Cancer Res. 11, 751-755
   Abstract »    Full Text »    PDF »
In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate.
R. J. Sanderson, M. A. Hering, S. F. James, M. M.C. Sun, S. O. Doronina, A. W. Siadak, P. D. Senter, and A. F. Wahl (2005)
Clin. Cancer Res. 11, 843-852
   Abstract »    Full Text »    PDF »
In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells.
P. Tassone, A. Gozzini, V. Goldmacher, M. A. Shammas, K. R. Whiteman, D. R. Carrasco, C. Li, C. K. Allam, S. Venuta, K. C. Anderson, et al. (2004)
Cancer Res. 64, 4629-4636
   Abstract »    Full Text »    PDF »
Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193-N-Acetyl {gamma} Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-Positive Human Carcinoma Cells and Xenografts.
E. R. Boghaert, L. Sridharan, D. C. Armellino, K. M. Khandke, J. F. DiJoseph, A. Kunz, M. M. Dougher, F. Jiang, L. B. Kalyandrug, P. R. Hamann, et al. (2004)
Clin. Cancer Res. 10, 4538-4549
   Abstract »    Full Text »    PDF »
Novel Cisplatin-Incorporated Polymeric Micelles Can Eradicate Solid Tumors in Mice.
N. Nishiyama, S. Okazaki, H. Cabral, M. Miyamoto, Y. Kato, Y. Sugiyama, K. Nishio, Y. Matsumura, and K. Kataoka (2003)
Cancer Res. 63, 8977-8983
   Abstract »    Full Text »    PDF »
Cure of SCID Mice Bearing Human B-Lymphoma Xenografts by an Anti-CD74 Antibody-Anthracycline Drug Conjugate.
G. L. Griffiths, M. J. Mattes, R. Stein, S. V. Govindan, I. D. Horak, H. J. Hansen, and D. M. Goldenberg (2003)
Clin. Cancer Res. 9, 6567-6571
   Abstract »    Full Text »    PDF »
Targeted Delivery in Primary and Metastatic Brain Tumors: Summary Report of the Seventh Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
N. D. Doolittle, L. E. Abrey, N. Ferrari, W. A. Hall, E. R. Laws, R. E. McLendon, L. L. Muldoon, D. Peereboom, D. R. Peterson, C. P. Reynolds, et al. (2002)
Clin. Cancer Res. 8, 1702-1709
   Abstract »    Full Text »    PDF »
High Affinity Restricts the Localization and Tumor Penetration of Single-Chain Fv Antibody Molecules.
G. P. Adams, R. Schier, A. M. McCall, H. H. Simmons, E. M. Horak, R. K. Alpaugh, J. D. Marks, and L. M. Weiner (2001)
Cancer Res. 61, 4750-4755
   Abstract »    Full Text »    PDF »
Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood.
Y. S. Chang, E. di Tomaso, D. M. McDonald, R. Jones, R. K. Jain, and L. L. Munn (2000)
PNAS 97, 14608-14613
   Abstract »    Full Text »    PDF »
Immunoconjugates of Geldanamycin and Anti-HER2 Monoclonal Antibodies: Antiproliferative Activity on Human Breast Carcinoma Cell Lines.
R. Mandler, C. Wu, E. A. Sausville, A. J. Roettinger, D. J. Newman, D. K. Ho, C. R. King, D. Yang, M. E. Lippman, N. F. Landolfi, et al. (2000)
J Natl Cancer Inst 92, 1573-1581
   Abstract »    Full Text »    PDF »
In Vivo Biodistribution of a Humanized Anti-Lewis Y Monoclonal Antibody (hu3S193) in MCF-7 Xenografted BALB/c Nude Mice.
K. Clarke, F.-T. Lee, M. W. Brechbiel, F. E. Smyth, L. J. Old, and A. M. Scott (2000)
Cancer Res. 60, 4804-4811
   Abstract »    Full Text »
Phase I Trial of the Anti-Lewis Y Drug Immunoconjugate BR96-Doxorubicin in Patients With Lewis Y-Expressing Epithelial Tumors.
M. N. Saleh, S. Sugarman, J. Murray, J. B. Ostroff, D. Healey, D. Jones, C. R. Daniel, D. LeBherz, H. Brewer, N. Onetto, et al. (2000)
J. Clin. Oncol. 18, 2282-2292
   Abstract »    Full Text »    PDF »
Complete Regression of Xenografted Human Carcinomas by Camptothecin Analogue-Carboxymethyl Dextran Conjugate (T-0128).
S. Okuno, M. Harada, T. Yano, S. Yano, S. Kiuchi, N. Tsuda, Y. Sakamura, J. Imai, T. Kawaguchi, and K. Tsujihara (2000)
Cancer Res. 60, 2988-2995
   Abstract »    Full Text »    PDF »
Antitumor Activity of N-(2-Hydroxypropyl)methacrylamide Copolymer-Mesochlorin e6 and Adriamycin Conjugates in Combination Treatments.
J.-G. Shiah, Y. Sun, C. M. Peterson, R. C. Straight, and J. Kopecek (2000)
Clin. Cancer Res. 6, 1008-1015
   Abstract »    Full Text »
Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.
D. B. Axworthy, J. M. Reno, M. D. Hylarides, R. W. Mallett, L. J. Theodore, L. M. Gustavson, F.-M. Su, L. J. Hobson, P. L. Beaumier, and A. R. Fritzberg (2000)
PNAS 97, 1802-1807
   Abstract »    Full Text »    PDF »
Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: Implications for the design of preclinical studies.
A. Nagy, A. Plonowski, and A. V. Schally (2000)
PNAS 97, 829-834
   Abstract »    Full Text »    PDF »
Enhanced Antitumor Activity of Paclitaxel in Combination with the Anticarcinoma Immunoconjugate BR96-Doxorubicin.
P. A. Trail, D. Willner, A. B. Bianchi, A. J. Henderson, M. D. TrailSmith, E. Girit, S. Lasch, I. Hellstrom, and K. E. Hellstrom (1999)
Clin. Cancer Res. 5, 3632-3638
   Abstract »    Full Text »    PDF »
Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx.
S. Mao, C. Gao, C.-H. L. Lo, P. Wirsching, C.-H. Wong, and K. D. Janda (1999)
PNAS 96, 6953-6958
   Abstract »    Full Text »    PDF »
Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer.
A. W. Tolcher, S. Sugarman, K. A. Gelmon, R. Cohen, M. Saleh, C. Isaacs, L. Young, D. Healey, N. Onetto, and W. Slichenmyer (1999)
J. Clin. Oncol. 17, 478
   Abstract »    Full Text »    PDF »
Construction, Expression, and Characterization of BD1-G28-5 sFv, a Single-chain Anti-CD40 Immunotoxin Containing the Ribosome-inactivating Protein Bryodin 1.
J. A. Francisco, S. L. Gawlak, and C. B. Siegall (1997)
J. Biol. Chem. 272, 24165-24169
   Abstract »    Full Text »    PDF »
A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab.
M. J. Rosok, D. E. Yelton, L. J. Harris, J. Bajorath, K.-E. Hellstrom, I. Hellstrom, G. A. Cruz, K. Kristensson, H. Lin, W. D. Huse, et al. (1996)
J. Biol. Chem. 271, 22611-22618
   Abstract »    Full Text »    PDF »
Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases.
F. Uckun, W. Evans, C. Forsyth, K. Waddick, L. Ahlgren, L. Chelstrom, A Burkhardt, J Bolen, and D. Myers (1995)
Science 267, 886-891
   Abstract »    PDF »
Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
C Renner, W Jung, U Sahin, R Denfeld, C Pohl, L Trumper, F Hartmann, V Diehl, R van Lier, and M Pfreundschuh (1994)
Science 264, 833-835
   Abstract »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)